Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs11554290
rs11554290
C 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs121913237
rs121913237
G 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs121913237
rs121913237
A 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs121913237
rs121913237
T 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs121913250
rs121913250
T 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs121913250
rs121913250
A 0.700 CausalMutation CLINVAR BRAF mutation predicts sensitivity to MEK inhibition. 16273091

2006

dbSNP: rs11554290
rs11554290
C 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs121913237
rs121913237
A 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs121913237
rs121913237
T 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs121913237
rs121913237
G 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs121913250
rs121913250
T 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs121913250
rs121913250
A 0.700 CausalMutation CLINVAR AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. 17699718

2007

dbSNP: rs11554290
rs11554290
C 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs121913237
rs121913237
A 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs121913237
rs121913237
G 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs121913237
rs121913237
T 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs121913250
rs121913250
T 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs121913250
rs121913250
A 0.700 CausalMutation CLINVAR Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. 20619739

2010

dbSNP: rs11554290
rs11554290
C 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs121913237
rs121913237
A 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs121913237
rs121913237
T 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs121913237
rs121913237
G 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs121913250
rs121913250
T 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs121913250
rs121913250
A 0.700 CausalMutation CLINVAR NRAS mutations are rare in colorectal cancer. 20736745

2010

dbSNP: rs11554290
rs11554290
C 0.700 CausalMutation CLINVAR Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. 21305640

2011